Short-term efficacy and safety of Risankizumab intensification and reinduction following an inadequate clinical response in Crohn's Disease. A multicenter retrospective study. - Fuentes-Valenzuela, E; Lillo, J; Caballero Mateos, A M; Fuentes Coronel, A; Alcaide Suarez, N; Lopez Martin, M D C; Rascarachi, G; Suarez Ferrer, C J; Fradejas Salazar, P M; Santos Fernandez, J; Velayos, B; Sicilia Aladren, B; et al. (Journal of Crohns & Colitis, 2026)